Amplify Weight Loss Drug & Treatment ETF (THNR)

Assets	$3.95M
Expense Ratio	0.59%
PE Ratio	19.04
Shares Out	130,000
Dividend (ttm)	$0.22
Dividend Yield	0.98%
Ex-Dividend Date	Dec 30, 2024
Payout Ratio	18.60%
1-Year Return	-16.00%

Volume	5,062
Open	22.48
Previous Close	22.50
Day's Range	22.44 - 22.55
52-Week Low	18.56
52-Week High	28.19
Beta	n/a
Holdings	24
Inception Date	May 21, 2024

About THNR

Fund Home Page

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: NYSEARCA
• Ticker Symbol: THNR
• ETF Provider: Amplify Investments
• Index Tracked: VettaFi Weight Loss Drug & Treatment Index

Top 10 Holdings

67.36% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	10.75%
Novo Nordisk A/S	NVO	8.38%
Regeneron Pharmaceuticals, Inc.	REGN	7.74%
Amgen Inc.	AMGN	6.97%
Gilead Sciences, Inc.	GILD	5.84%
Chugai Pharmaceutical Co., Ltd.	4519	5.79%
AbbVie Inc.	ABBV	5.63%
AstraZeneca PLC	AZN	5.48%
Pfizer Inc.	PFE	5.42%
Merck & Co., Inc.	MRK	5.36%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 30, 2024	$0.2199	Dec 31, 2024